| Home | E-Submission | Sitemap | Contact Us |  
top_img
Cancer Research and Treatment > Volume 35(5); 2003 > Article
Cancer Research and Treatment 2003;35(5): 407-410. doi: https://doi.org/10.4143/crt.2003.35.5.407
Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study
Myung Ju Ahn, Ho Suck Oh, Jung Hye Choi, Young Yeul Lee, In Soon Kim, Il Young Choi, Oh Young Lee, Heung Woo Lee
1Department of Internal Medicine, College of Medicine,Hanyang University, Seoul, Korea. ahnmj@hanyang.ac.kr
2Department of General Surgery, College of Medicine, HanyangUniversity, Seoul, Korea.
  Published online: October 31, 2003.
ABSTRACT
PURPOSE:
To evaluate the efficacy and toxicity of oxaliplatin and capecitabine in patients with metastatic colorectal cancer.
MATERIALS AND METHODS:
Between December 2001 and April 2003, fourteen patients were enrolled in this study. Oxaliplatin, 80 mg/m(2), was administered intravenously on day 1, and capecitabine, 1, 250 mg/m(2) bid po (total daily dose 2, 500 mg/m(2)), was given on days 1~14 of 3 week cycles.
RESULTS:
The median age of the patients was 57 years (range: 41~74), and the most common sites of metastasis were liver, lung or lymph node. Of the 12 evaluable patients, the overall response rate was 41.7%, but with no complete response. The median response duration and median progression free survival of 12 patients were 42 and 24.4 weeks, respectively. The median overall survival was not reached. A median 6 (range: 1~9), and a total 80, cycles were administered to 14 patients. 80 cycles were evaluable for toxicity. The most common hematological toxicities were NCI grades I/II anemia (45%), leucopenia (33.75%) and thrombocytopenia (17.5%). The most common non-hematological toxicities were nausea/ vomiting (28.75/5%) and neurotoxicity (8.75%). Hand and foot syndrome was noted in only 3.75%. There was no life-threatening toxicity.
CONCLUSION:
Oxaliplatin and oral capecitabine combination chemotherapy showed significant activity and favorable toxicity in patients with metastatic colorectal cancer. Further studies, with larger numbers of patients and long-tern follow-up will be needed.
Key words: Colorectal neoplasm;Chemotherapy;Oxaliplatin;Capecitabine
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2PI